| 摘要 |
Discloses an isolated meditope-enabled antibody or fragment thereof, comprising: a heavy chain variable (VH) region, a heavy chain constant region (CH) or portion thereof, a light chain variable (VL) region comprising a threonine, serine, or aspartate at position 40, a residue other than glycine at position 41, a residue other than phenylalanine at position 83, and an aspartate or asparagine at position 85, according to Kabat numbering, and a light chain constant region (CL) or portion thereof, wherein the meditope-enabled antibody is a meditope-enabled variant of a human or humanised template antibody, which variant contains a plurality of framework region (FR) modifications, according to Kabat numbering, compared to the template antibody, said FR modifications being only at positions selected from the group consisting of positions 8, 9, 10, 38, 39, 40, 41, 42, 43, 44, 45, 82, 83, 84, 85, 86, 87, 99, 100, 101, 102, 103, 104, and 105 of the light chain of said template antibody, according to Kabat numbering, and positions 6, 9, 38, 39, 40, 41, 42, 43, 44, 45, 84, 86, 87, 88, 89, 90, 91, 103, 104, 105, 106, 107, 108, 109, and 110 of the heavy chain of said template antibody, according to Kabat numbering; and the meditope-enabled antibody or fragment binds to a meditope comprising a peptide of SEQ ID NO: 1, via a meditope binding site, wherein the sequence is as defined in the compete specification. |
